Gizem Kaynar Beyaz^1,*, Ahmet Kirbas², Sevgi Kalkanli Tas¹

BIOCELL, Vol.50, No.1, 2026, DOI:10.32604/biocell.2025.072368 - 23 January 2026

Abstract Peripheral artery disease (PAD) remains a significant global health issue, with current treatments primarily focused on relieving symptoms and addressing macrovascular issues. However, critical immunoinflammatory mechanisms are often overlooked. Recent evidence suggests that monocyte phenotypic plasticity plays a central role in PAD development, affecting atherogenesis, plaque progression, ischemia-reperfusion injury, and chronic ischemic remodeling. This narrative review aims to summarize the latest advances (2023–2025) in understanding monocyte diversity, functional states, and their changes throughout different stages of PAD. We discuss both established and emerging biomarkers, such as circulating monocyte subset proportions, functional assays, immune checkpoint expression, More >

Harpreet Kaur^1,*, Dhrubalochan Rana², Sowvik Bag², Paramjeet Singh³

Oncology Research, Vol.34, No.2, 2026, DOI:10.32604/or.2025.071209 - 19 January 2026

Abstract The prolonged and intricate history of oncological treatments has transitioned significantly since the introduction of chemotherapy. Substantial therapeutic benefits in cancer therapy have been achieved by the integration of conventional treatments with molecular biosciences and omics technologies. Human epidermal growth factor receptor, hormone receptors, and angiogenesis factors are among the established therapies in tumor reduction and managing side effects. Novel targeted therapies like KRAS G12C, Claudin-18 isoform 2 (CLDN18.2), Trophoblast cell-surface antigen 2 (TROP2), and epigenetic regulators emphasize their promise in advancing precision medicine. However, in many cases, the resistance mechanisms associated with these interventions… More > Graphic Abstract

Fu Zhang^1,2, Miao Lin^1,2, Yuancong Jiang³, Fangjian Zhou^1,2,*

European Cytokine Network, Vol.36, No.1, pp. 1-5, 2025, DOI:10.1684/ecn.2025.0500

Abstract Interleukin-33 (IL-33), a key member of the IL-1 family, plays a significant role in inflammation and cancer. Its classic receptors, ST2 and IL-1 receptor accessory protein (IL-1RAcP), are predominantly expressed in immune cells such as T helper 2 (Th2) cells and mast cells. Recent studies have highlighted the involvement of IL-33 in breast cancer, demonstrating its ability to exert dual functional effects by modulating both innate and adaptive immune responses within the tumour microenvironment. However, the precise molecular mechanisms linking IL-33 to breast cancer pathogenesis and its potential as a target for molecularly targeted therapies More >

Amber Hassan¹, Badr Hafiz², Taghreed Alsinani³, Rakan Bokhari⁴, Dahlia Mirdad⁵, Awab Tayyib⁵, Alaa Alkhotani⁶, Ahmad Fallata⁷, Iman Mirza⁸, Eyad Faizo^9,10, Saleh Baeesa², Huda Alghefari¹¹, Maher Kurdi^11,*

Oncology Research, Vol.33, No.11, pp. 3293-3325, 2025, DOI:10.32604/or.2025.070031 - 22 October 2025

Abstract Background: Glioblastoma (GBM) remains the most aggressive primary brain tumour in adults, marked by pronounced cellular heterogeneity, diffuse infiltration, and resistance to conventional treatment. In recent years, transcriptomic profiling has provided valuable insights into the molecular mechanisms that govern the progression of glioblastoma. This systematic review aims to synthesise the current literature on dysregulated gene expression in GBM, focusing on gene signatures associated with stemness, immune modulation, extracellular matrix remodelling, metabolic adaptation, and therapeutic resistance. Methods: We conducted a systematic search of PubMed, The Cancer Genome Atlas (TCGA), Chinese Glioma Genome Atlas (CGGA), and the GlioVis… More >

Bruno Špiljak^1,#, Bojan Poposki^2,#, Stjepanka Lešić^3,*

Oncology Research, Vol.33, No.11, pp. 3269-3292, 2025, DOI:10.32604/or.2025.068395 - 22 October 2025

Abstract Head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer with high recurrence rates and prevalent resistance to therapeutic interventions. Tumor behavior is largely dependent on the tumor microenvironment (TME) that includes immune cells, stromal components, cancer-associated fibroblasts (CAFs), the extracellular matrix (ECM), and an associated cytokine network. In this review, we examine principal mechanisms of the tumorigenic transformation, encompassing immune checkpoint disruption, therapy resistance mediated through CAFs, the contribution of hypoxic niches, and several metabolic dependencies that hold potential as future targets. Novel therapeutics developed and/or repurposed, such as immune checkpoint inhibitors (ICIs),… More >

FANG CHEN¹, DONGQIANG YANG², YUHUA RU³, SHAN CAO¹, AISHE GAO¹

Oncology Research, Vol.33, No.7, pp. 1799-1800, 2025, DOI:10.32604/or.2025.064363 - 26 June 2025

Abstract This article has no abstract. More >

YU HONG^1,#, YUNXIANG TANG^1,#, WENYAN ZHOU¹, HANYUE LUO², LINLIN BU², HUI QIU^3,*, QIUJI WU^3,*

Oncology Research, Vol.33, No.6, pp. 1347-1361, 2025, DOI:10.32604/or.2025.059327 - 29 May 2025

Abstract As a rising immune checkpoint on tumor cells, CD24 is closely related to tumorigenesis and progression. CD24 can directly regulate the malignant behavior of tumor cells and indirectly inhibit the function of immune cells in the meantime, which promotes the immune escape of tumor cells, induces cancer invasion and causes poor prognosis. The basic principle of cancer treatment is to induce cell death and inhibit cell survival. Resistance to chemoradiotherapy is a critical challenge in oncology, which limits the effectiveness of anti-cancer treatments. Many studies have shown a strong association between CD24 and chemoradiotherapy More >

Xiongwei Cui, Yunchao Wang, Qiang Wei^*

CMC-Computers, Materials & Continua, Vol.83, No.3, pp. 4939-4959, 2025, DOI:10.32604/cmc.2025.063592 - 19 May 2025

Abstract The development of the Internet of Things (IoT) has brought convenience to people’s lives, but it also introduces significant security risks. Due to the limitations of IoT devices themselves and the challenges of re-hosting technology, existing fuzzing for IoT devices is mainly conducted through black-box methods, which lack effective execution feedback and are blind. Meanwhile, the existing static methods mainly rely on taint analysis, which has high overhead and high false alarm rates. We propose a new directed fuzz testing method for detecting bugs in web service programs of IoT devices, which can test IoT… More >

Giuseppe Carota¹, Lucia Di Pietro^2,3, Vincenzo Cardaci⁴, Anna Privitera^1,2, Francesco Bellia¹, Valentina Di Pietro⁵, Giuseppe Lazzarino¹, Barbara Tavazzi⁶, Angela Maria Amorini¹, Giacomo Lazzarino⁶, Giuseppe Caruso^6,7,*

BIOCELL, Vol.49, No.4, pp. 563-578, 2025, DOI:10.32604/biocell.2025.062176 - 30 April 2025

Abstract Carnosine (β-alanyl-L-histidine) is a naturally occurring endogenous peptide widely distributed in excitable tissues, such as the heart and brain. Over the years, several beneficial effects of carnosine have been discussed well in scientific literature. In particular, this dipeptide is well-known for its antioxidant, anti-inflammatory, and anti-aggregation activities. It is of great interest in the context of numerous systemic and neurodegenerative diseases, besides performing important “side activities” such as metal chelation and pH-buffering. Despite a plethora of preclinical and clinical data supporting carnosine’s therapeutic potential, researchers are still searching for new pharmacological targets that better highlight More >

HYUNG SEOK KIM^*

Oncology Research, Vol.33, No.5, pp. 995-1000, 2025, DOI:10.32604/or.2025.060616 - 18 April 2025

Abstract The discovery of glycosylated RNA molecules, known as glycoRNAs, introduces a novel dimension to cellular biology. This commentary explores the transformative findings surrounding glycoRNAs, emphasizing their unique roles in cancer progression and the therapeutic opportunities they present. GlycoRNAs, through interactions with lectins and immune receptors, may contribute to tumor immune evasion. Moreover, the therapeutic potential of this emerging knowledge includes interventions targeting glycoRNA synthesis and modulation of associated signaling pathways. By highlighting these critical insights, this commentary aims to encourage the development of innovative strategies that could improve cancer prognosis and treatment. More >